Annelise Segers

4.5k total citations · 4 hit papers
31 papers, 2.8k citations indexed

About

Annelise Segers is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Annelise Segers has authored 31 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Internal Medicine, 22 papers in Cardiology and Cardiovascular Medicine and 6 papers in Hematology. Recurrent topics in Annelise Segers's work include Venous Thromboembolism Diagnosis and Management (23 papers), Atrial Fibrillation Management and Outcomes (16 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Annelise Segers is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (23 papers), Atrial Fibrillation Management and Outcomes (16 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Annelise Segers collaborates with scholars based in United States, Netherlands and Canada. Annelise Segers's co-authors include Harry R. Büller, Gary E. Raskob, Jeffrey I. Weitz, Peter Verhamme, Martin H. Prins, Michele Mercuri, Nick van Es, George Zhang, Michael Grosso and David Gailani and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Annelise Segers

29 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

2017 1.1k citations Gary E. Raskob, Nick van Es et al. New England Journal of Medicine profile →
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

2014 455 citations Harry R. Büller, Claudette Bethune et al. New England Journal of Medicine profile →
Abelacimab for Prevention of Venous Thromboembolism

2021 180 citations Peter Verhamme, Annelise Segers et al. New England Journal of Medicine profile →
Milvexian for the Prevention of Venous Thromboembolism

2021 162 citations Jeffrey I. Weitz, John Strony et al. New England Journal of Medicine profile →

Peers

Annelise Segers

CCM

HEMAT

GENET

EMS

Sergio Siragusa Italy

Mauro Silingardi Italy

B. Kemkes‐Matthes Germany

Jeannine Kassis Canada

Sean Dolan Canada

José Mateo Spain

FR Rosendaal Netherlands

Ansgar Weltermann Austria

Gregory C. Connolly United States

Tzu‐Fei Wang Canada

Sergio Siragusa Italy

Annelise Segers

748 ×0.4

595 ×0.3

CCM

960 ×1.4

HEMAT

470 ×0.8

GENET

144 ×0.3

EMS

Citations per year, relative to Annelise Segers Annelise Segers (= 1×) peers Sergio Siragusa

Countries citing papers authored by Annelise Segers

Since Specialization

Citations

This map shows the geographic impact of Annelise Segers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annelise Segers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annelise Segers more than expected).

Fields of papers citing papers by Annelise Segers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annelise Segers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annelise Segers. The network helps show where Annelise Segers may publish in the future.

Co-authorship network of co-authors of Annelise Segers

This figure shows the co-authorship network connecting the top 25 collaborators of Annelise Segers. A scholar is included among the top collaborators of Annelise Segers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annelise Segers. Annelise Segers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weitz, Jeffrey I., Aaron Kithcart, Meagan P. O’Brien, et al.. (2025). Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. The Lancet. 406(10519). 2551–2563.

Bosch, Floris T.M., Michael Grosso, Annelise Segers, et al.. (2025). Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. Journal of Thrombosis and Haemostasis. 23(7). 2255–2261. 2 indexed citations

Bosch, Floris T.M., Frits I. Mulder, Menno V. Huisman, et al.. (2021). Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis. 19(12). 3008–3017. 12 indexed citations

Tritschler, Tobias, Noémie Kraaijpoel, Nicole Langlois, et al.. (2020). Development of a standardized definition of pulmonary embolism‐related death: A cross‐sectional survey of international thrombosis experts. Journal of Thrombosis and Haemostasis. 18(6). 1415–1420. 8 indexed citations

Tritschler, Tobias, Noémie Kraaijpoel, Philippe Girard, et al.. (2020). Definition of pulmonary embolism‐related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18(6). 1495–1500. 37 indexed citations

Mulder, Frits I., Marcello Di Nisio, Cihan Ay, et al.. (2019). Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal. 55(2). 1901697–1901697. 31 indexed citations

Weitz, Jeffrey I., Gary E. Raskob, Michael R. Lassen, et al.. (2019). COMPARISON OF JNJ9375, A THROMBIN EXOSITE 1-DIRECTED ANTIBODY, WITH APIXABAN FOR THROMBOPROPHYLAXIS AFTER ELECTIVE KNEE REPLACEMENT SURGERY: TEXT-TKR STUDY. Journal of the American College of Cardiology. 73(9). 2047–2047. 1 indexed citations

Weitz, Jeffrey I., Annelise Segers, Gary E. Raskob, et al.. (2019). Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis. Journal of Thrombosis and Haemostasis. 17(12). 2081–2088. 3 indexed citations

Nisio, Marcello Di, Nick van Es, Marc Carrier, et al.. (2019). Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study. Journal of Thrombosis and Haemostasis. 17(11). 1866–1874. 44 indexed citations

10.

Mulder, Frits I., Nick van Es, Noémie Kraaijpoel, et al.. (2018). Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research. 164. S194–S194. 5 indexed citations

11.

Brekelmans, Marjolein, Walter Ageno, Ludo F.M. Beenen, et al.. (2016). Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3(9). e437–e445. 25 indexed citations

12.

Raskob, Gary E., Walter Ageno, Alexander T. Cohen, et al.. (2016). Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3(5). e228–e236. 46 indexed citations

13.

Wells, Philip, Annelise Segers, Walter Ageno, et al.. (2016). Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. Thrombosis and Haemostasis. 116(10). 747–753. 30 indexed citations

14.

Raskob, Gary E., Nick van Es, Annelise Segers, et al.. (2016). Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. The Lancet Haematology. 3(8). e379–e387. 117 indexed citations

15.

Nakamura, Mashio, Chen Wang, Doyeun Oh, et al.. (2015). Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai‐VTE trial. Journal of Thrombosis and Haemostasis. 13(9). 1606–1614. 36 indexed citations

16.

Büller, Harry R., Claudette Bethune, Sanjay Bhanot, et al.. (2014). Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. New England Journal of Medicine. 372(3). 232–240. 455 indexed citations breakdown →

17.

Raskob, Gary E., Harry R. Büller, Martin H. Prins, et al.. (2013). Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis. 11(7). 1287–1294. 64 indexed citations

18.

Büller, Harry R., David Deitchman, Martin H. Prins, & Annelise Segers. (2008). Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study. Journal of Thrombosis and Haemostasis. 6(8). 1313–1318. 193 indexed citations

19.

Neylan, John F., Benoı̂t Stijlemans, Karl R. Brinker, et al.. (1997). Detection of clinically relevant antibodies pretransplant and posttransplant with PRA-STAT. Transplantation Proceedings. 29(1-2). 330–332. 3 indexed citations

20.

Segers, Annelise, et al.. (1970). [Physiopathology and treatment of the drowning victim].. PubMed. 50(4). 295–302. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact